Evaxion Biotech A/S (EVAX)
Evaxion Biotech A/S Statistics
Share Statistics
Evaxion Biotech A/S has 315.83K shares outstanding. The number of shares has increased by 0.02% in one year.
| Shares Outstanding | 315.83K |
| Shares Change (YoY) | 0.02% |
| Shares Change (QoQ) | -0.48% |
| Owned by Institutions (%) | 15.81% |
| Shares Floating | 286.63K |
| Failed to Deliver (FTD) Shares | 1.86K |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.02 and the forward PE ratio is 3.79. Evaxion Biotech A/S's PEG ratio is 0.
| PE Ratio | -0.02 |
| Forward PE | 3.79 |
| PS Ratio | 0.07 |
| Forward PS | 0 |
| PB Ratio | -0.14 |
| P/FCF Ratio | -0.02 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Evaxion Biotech A/S.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.01, with a Debt / Equity ratio of -6.11.
| Current Ratio | 2.01 |
| Quick Ratio | 2.01 |
| Debt / Equity | -6.11 |
| Debt / EBITDA | -1.03 |
| Debt / FCF | -0.78 |
| Interest Coverage | -15.31 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $72.7K |
| Profits Per Employee | $-229.72K |
| Employee Count | 46 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -788K |
| Effective Tax Rate | 6.94% |
Stock Price Statistics
The stock price has increased by -92.15% in the last 52 weeks. The beta is -0.25, so Evaxion Biotech A/S's price volatility has been lower than the market average.
| Beta | -0.25 |
| 52-Week Price Change | -92.15% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 8.46 |
| Relative Strength Index (RSI) | 52.33 |
| Average Volume (20 Days) | 1.35M |
Income Statement
In the last 12 months, Evaxion Biotech A/S had revenue of 3.34M and earned -10.57M in profits. Earnings per share was -200.
| Revenue | 3.34M |
| Gross Profit | 3.34M |
| Operating Income | -14.73M |
| Net Income | -10.57M |
| EBITDA | -9.79M |
| EBIT | -10.39M |
| Earnings Per Share (EPS) | -200 |
Balance Sheet
The company has 5.05M in cash and 10.1M in debt, giving a net cash position of -5.05M.
| Cash & Cash Equivalents | 5.05M |
| Total Debt | 10.1M |
| Net Cash | -5.05M |
| Retained Earnings | -118.54M |
| Total Assets | 12.48M |
| Working Capital | 4.4M |
Cash Flow
In the last 12 months, operating cash flow was -12.94M and capital expenditures 0, giving a free cash flow of -12.94M.
| Operating Cash Flow | -12.94M |
| Capital Expenditures | 0 |
| Free Cash Flow | -12.94M |
| FCF Per Share | -12.06 |
Margins
Gross margin is 100%, with operating and profit margins of -440.55% and -316%.
| Gross Margin | 100% |
| Operating Margin | -440.55% |
| Pretax Margin | -339.56% |
| Profit Margin | -316% |
| EBITDA Margin | -292.64% |
| EBIT Margin | -440.55% |
| FCF Margin | -386.96% |
Dividends & Yields
EVAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for EVAX is $10, which is 509.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 509.8% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jan 14, 2025. It was a backward split with a ratio of 1:5.
| Last Split Date | Jan 14, 2025 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | -15.44 |
| Piotroski F-Score | 5 |